



Special Seminar

Prof. Adrian Krainer

Cold Spring Harbor Laboratories, USA

**From Base Pairs to Bedside:
Antisense Therapeutics for Splicing
Modulation**

Krainer is the recipient of an Honorary
Doctorate from Tel Aviv University in May
2019 for the invention of the first RNA-
targeted antisense therapeutic Spinraza,
the first approved drug to treat the
neurodegenerative disease spinal muscular
atrophy

14/5/19

12:00

**Lola hall
Sackler Building**

**Host:
Prof. Gil Ast**